Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke: The INSTANT Randomized Clinical Trial.
INSTANT Trial Authors for the INSTANT Investigators, Xianghong Liu, Fan Zhang...
https://pubmed.ncbi.nlm.nih.gov/42100960/Actively Recruiting
Led by Second Affiliated Hospital of Guangxi Medical University · Updated on 2025-12-24
348
Participants Needed
38
Research Sites
12 weeks
Total Duration
Researchers are studying the safety and effectiveness of early use of tirofiban in patients who have acute ischemic stroke and are treated with tenecteplase. This study is exploring whether adding tirofiban soon after tenecteplase can reduce the risk of blood clot re-blockage in the brain, which happens in some patients after initial treatment. The study is a phase 3 trial aiming to improve stroke outcomes by preventing this reocclusion. Participants first receive tenecteplase intravenously for stroke treatment. Those who meet the study criteria are then randomly assigned to receive either tirofiban or a placebo. Tirofiban or placebo is given intravenously starting as soon as possible after randomization, initially as a higher dose for 30 minutes, followed by a continuous lower dose infusion for nearly 48 hours. After 24 hours, patients receive aspirin andor clopidogrel or their placebos, then after 44 hours, antiplatelet therapy with aspirin andor clopidogrel continues until the 90-day follow-up. During the study, participants undergo assessments including neurological exams and monitoring for bleeding or other adverse events. The main outcome measured is excellent functional recovery 90 days after randomization. Other outcomes include disability levels, neurological improvement, quality of life, bleeding events, and mortality. Safety and serious adverse events are tracked through the 90-day period to evaluate treatment effects and risks.
CONDITIONS
Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke
D
Deyan Kong, MD
G
Guoyong Zeng, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Second Affiliated Hospital of Guangxi Medical University
Lead Sponsor
Ganzhou City People's Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 2 days
Participants receive intravenous tenecteplase followed by a randomized assignment to either tirofiban or placebo infusions starting within 4 to 24 hours after tenecteplase treatment. The infusion lasts approximately 48 hours. Aspirin and/or clopidogrel placebo or active tablets are given orally starting 24 to 44 hours after randomization and continued through the treatment period.
1 baseline visit and assessments during infusion
Duration - 90 days
Participants are monitored for outcomes and safety, including functional status and adverse events, for 90 days after randomization.
Follow-up visits up to 90 days
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
INSTANT Trial Authors for the INSTANT Investigators, Xianghong Liu, Fan Zhang...
https://pubmed.ncbi.nlm.nih.gov/42100960/Second Affiliated Hospital of Guangxi Medical University
Lead Sponsor
Ganzhou City People's Hospital
Collaborating Sponsor